A clinical trial to investigate immunotherapy (IMO-2125) in the skin of patients with a melanoma which is at least 2 millimeters thick
- Conditions
- MelanomaMelanoomEarly-stage melanomaVroeg stadium melanoom
- Registration Number
- NL-OMON26696
- Lead Sponsor
- VU University medical center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 214
Inclusion Criteria
1.Patients must be willing and able to sign the informed consent and comply with the study protocol.
2.Must be ≥18 years of age.
Exclusion Criteria
1.Known hypersensitivity to any oligodeoxynucleotide.
2.Active autoimmune disease requiring disease-modifying therapy at the time of screening.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of tumor positive sentinel lymph nodes (SLN)
- Secondary Outcome Measures
Name Time Method 1) Frequency and activation state of lymph node resident (LNR) conventional dendritic cells (DC) and melanoma antigen-specific T cell responses in the SLN and peripheral blood.<br /><br>2) RFS<br /><br>3) OS<br>